When does Parkinson disease start?

Archives of Neurology

Volumn 67, Issue 7, 2010, Pages 798-801

  Savica, Rodolfo ^a   Rocca, Walter A ^a   Ahlskog, J Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE;

ANEMIA; ANXIETY DISORDER; CONSTIPATION; DEPRESSION; HUMAN; LEWY BODY; MOTOR DYSFUNCTION; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; REM SLEEP; REVIEW; RISK ASSESSMENT; SLEEP DISORDER; SMELLING DISORDER; STRIATONIGRAL DEGENERATION;

AGE OF ONSET; ANEMIA; ANXIETY DISORDERS; CONSTIPATION; DISEASE PROGRESSION; HUMANS; OLFACTION DISORDERS; PARKINSON DISEASE; REM SLEEP BEHAVIOR DISORDER;

EID: 77955016727     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.135     Document Type: Review

References (46)

1. Elbaz A, Bower JH, Peterson BJ, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol. 2003;60(1):91-96.
2. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology. 2007;69(17):1701-1711.
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(pt 5):2283-2301.
4. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):378-382.
5. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996;119(pt 2):585-591. (Pubitemid 26149370)
6. 18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64(3):314-319.
7. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001;57(3):456-462.
8. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology. 2009; 73(21):1752-1758.
9. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord. 2003; 18(6):646-651. (Pubitemid 36790279)
10. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000; 15(4):669-677.
11. Bower JH, Grossardt BR, Maraganore DM, et al. Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord. In press.
12. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46(2):388-393. (Pubitemid 126425731)
13. Uchiyama M, Isse K, Tanaka K, et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology. 1995;45(4):709-712.
14. Boeve BF, Dickson DW, Olson EJ, et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 2007;8(1):60-64.
15. Stiasny-Kolster K, Doerr Y, Möller JC, et al. Combination of "idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128(pt 1):126-137.
16. Savica R, Grossardt BR, Carlin JM, et al. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology. 2009;73(17):1381-1387.
17. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24(2):197-211.
18. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006;396(1):67-72. (Pubitemid 43233790)
19. Braak H, Sastre M, Bohl JRE, de Vos RAI, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007;113(4):421-429.
20. Beach TG, Adler CH, Lue L, et al; Arizona Parkinson's Disease Consortium. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117(6):613-634.
21. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology. 1992;42(4):726-732.
22. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord. 1997;12 (6):946-951.
23. Petrovitch H, Abbott RD, Ross GW, et al. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov Disord. 2009;24(3):371-376.
24. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders? a cohort study. Neurology. 2007;68(23):2012-2018.
25. Ahlskog JE. Parkinson's Disease Treatment Guide for Physicians. New York, NY: Oxford University Press; 2009.
26. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123 (pt 2):331-339.
27. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001;16(4):622-630.
28. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(pt 11): 2770-2788.
29. Eisensehr I, Linke R, Tatsch K, et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters: IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep. 2003;26(5):507-512.
30. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26(6):719-723.
31. Shinde S, Pasupathy K. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson's disease: preliminary study. Neurol India. 2006;54(4):390-393. (Pubitemid 44870691)
32. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD Jr, Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci. 1991;104(2):203-208.
33. Peters R, Burch L, Warner J, Beckett N, Poulter R, Bulpitt C. Haemoglobin, anaemia, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr. 2008;8:18.
34. Atti AR, Palmer K, Volpato S, Zuliani G, Winblad B, Fratiglioni L. Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging. 2006; 27(2):278-284.
35. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008;63(2):167-173.
36. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006;21(12):2062-2067.
37. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004;56(2):173-181.
38. Ponsen MM, Stoffers D, Twisk JWR, Wolters EC, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord. 2009;24(7):1060-1065.
39. Nilsson FM, Kessing LV, Sørensen TM, Andersen PK, Bolwig TG. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand. 2002;106(3):202-211.
40. Schuurman AG, van den Akker M, Ensinck KTJL, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology. 2002; 58(10):1501-1504. (Pubitemid 34552956)
41. Leentjens AFG, Van den Akker M, Metsemakers JFM, Lousberg R, Verhey FRJ. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord. 2003;18(4):414-418.
42. Alonso A, García Rodriguez LA, Logroscino G, Hernán MA. Use of antidepressants and the risk of Parkinson's disease: a prospective study. J Neurol Neurosurg Psychiatry. 2009;80(6):671-674.
43. Behari M, Srivastava AK, Das RR, Pandey RM. Risk factors of Parkinson's disease in Indian patients. J Neurol Sci. 2001;190(1-2):49-55.
44. Frigerio R, Fujishiro H, Ahn TB, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies [published online June 26, 2009]? Neurobiol Aging. doi:10.1016/j.neurobiolaging.2009.05. 019.
45. Klos KJ, Ahlskog JE, Josephs KA, et al. α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology. 2006;66(7):1100-1102.
46. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008; 115(4):399-407.